Use of Angiotensin II for Post Cardiopulmonary Bypass Vasoplegic Syndrome

Authors

Adam Evans, Morristown Medical Center
Michael T. McCurdy, University of Maryland School of Medicine
Menachem Weiner, Icahn School of Medicine at Mount Sinai
Bledi Zaku, Morristown Medical Center
Jonathan H. Chow, University of Maryland School of Medicine

Document Type

Journal Article

Publication Date

7-1-2019

Journal

Annals of Thoracic Surgery

Volume

108

Issue

1

DOI

10.1016/j.athoracsur.2018.11.047

Abstract

© 2019 The Society of Thoracic Surgeons Angiotensin II is a novel vasopressor recently approved for the treatment of vasodilatory shock. We describe a case in which Angiotensin II was used to treat post–cardiopulmonary bypass vasoplegic syndrome in a patient who was refractory to standard vasopressors and other rescue therapies. Despite requiring high-dose vasopressors, the patient was extubated within 24 hours and has met key quality metrics defined by The Society of Thoracic Surgeons.

APA Citation

Evans, A., McCurdy, M., Weiner, M., Zaku, B., & Chow, J. (2019). Use of Angiotensin II for Post Cardiopulmonary Bypass Vasoplegic Syndrome. Annals of Thoracic Surgery, 108 (1). http://dx.doi.org/10.1016/j.athoracsur.2018.11.047